自身免疫性肝病治疗药物的研究进展

Research progress of therapeutic drugs for autoimmune liver disease

自身免疫性肝病主要是由于自身免疫系统异常而导致的慢性肝脏疾病。临床上自身免疫性肝病主要包括三种类型,分别为自身免疫性肝炎、原发性胆汁性胆管炎以及原发性硬化性胆管炎。近些年,自身免疫性肝病受到人们越来越多的关注,已经成为医学界研究的热点问题之一。自身免疫性肝病的药物治疗主要采用糖皮质激素或者免疫抑制剂进行治疗,但是由于不同类型的自身免疫性肝病在药物治疗方面具有不同的特点,因此在实际治疗过程中,应该针对自身免疫性肝病的类型以及患者的具体情况,采用针对性的药物治疗方式。很多专家学者在自身免疫性肝病的治疗药物方面开展大量的理论和临床研究工作,并取得了一定进展。本文对近些年关于自身免疫性肝病的治疗药物研究进展进行综述,以期为临床自身免疫性肝病的治疗提供借鉴。

Autoimmune liver disease is a chronic liver disease caused by abnormal autoimmune system.Clinical autoimmune liver disease mainly includes three typesautoimmune hepatitis,primary biliary cholangitis and primary sclerosing cholangitis.In recent years, autoimmune liver disease has attracted more and more attention,and has become one of the hot issues in medical research.Gluocorticoids or immunosuppressive agents are mainly used in the treatment of autoimmune liver diseases.However,because different types of autoimmune liver diseases have different characteristics in drug treatment,so we should adopt targeted drug treatment according to the type of autoimmune liver disease and the specific situation of patients in the actual treatment process.Targeted drug therapy is adopted.Many experts and scholars have carried out a lot of theoretical and clinical research work in the treatment of autoimmune liver disease,and made some progress.This article reviews the research progress in the treatment of autoimmune liver disease in recent years, in order to provide reference for the clinical treatment of autoimmune liver disease.